Identifying new Risk Markers and Potential Targets for Coronary Artery Disease: The Value of the Lipidome and Metabolome
Identifying new Risk Markers and Potential Targets for Coronary Artery Disease: The Value of the Lipidome and Metabolome
复制标题
DOI：
10.1007/s10557-016-6651-8
复制
发表时间：
2016-01-01
影响因子：
3.4
通讯作者：
Laaksonen, Reijo
中科院分区：
文献类型：
--
作者：
Laaksonen, Reijo
本系统综述的目的是总结已发表的有关冠状动脉疾病的脂质组学和代谢组学风险标记物的数据。研究是通过 PubMed 的文献检索确定的。已发表的数据表明，代谢物和脂质的分析为我们提供了一个机会，以增加我们对与动脉粥样硬化性冠状动脉疾病的发生和进展相关的生物过程的了解。显然，先进的分析技术能够检测和识别大量分子，这些分子可能比心血管领域目前使用的生物标志物具有重要的结构和功能作用。许多报告表明，新型生物标志物可用于改善风险分层和不同治疗的患者选择。此外，此类新标记物应该有助于监测治疗效果和安全性以及生活方式的改变。到目前为止，已经确定了大量与心血管事件风险相关的候选生物标记物，但很少有通过临床和分析验证并进入临床使用的。因此，医生在日常临床常规中使用这些新颖测试的意愿尚未得到真正的测试。
This systematic review was performed to summarize published data on lipidomic and metabolomic risk markers of coronary artery disease.Studies were identified from a literature search of PubMed.Published data shows that analysis of metabolites and lipids offers an opportunity to increase our knowledge of the biological processes related to development and progression of atherosclerotic coronary disease. It is evident that advanced analytical technologies are able to detect and identify a large number of molecules that may have important structural and functional roles over and above currently used biomarkers in the cardiovascular field. It is suggested in a number of reports that the novel biomarkers can be used to improve risk stratification and patient selection for different treatments. Also, monitoring treatment efficacy and safety as well as lifestyle changes should be facilitated by such novel markers.Until now a plethora of biomarker candidates associated with cardiovascular event risk have been identified, but very few have passed through clinical and analytical validation and found their way into clinical use. Consequently, the appetite of physicians to use these novel tests in daily clinical routine has not yet been truly tested.